In the article titled "Cytoprotective and Cytotoxic Effects of Rice Bran Extracts in Rat H9c2(2-1) Cardiomyocytes" \[[@B1]\], errors in statistical analyses for inhibitory concentration (IC~50~) have resulted in incorrect tabulations of data for both Tables [2](#tab1){ref-type="table"} and [4](#tab2){ref-type="table"}. The corrected versions of both tables are as below.

Accordingly, in the "Results" (Section 3.1), the text reading "*Based on the results ([Table 2](#tab1){ref-type="table"}), the IC~50~ values of RBE of BJLN were in the range of 61.67 to 64.57 μg/mL over 24, 48, and 72* hours *of incubation time*." should be corrected to "*Based on the results ([Table 2](#tab1){ref-type="table"}), the IC~50~ values of RBE of BJLN were in the range of 59.57 to 64.27 μg/mL over 24, 48, and 72 hours of incubation time*.", and "*Based on the results, the IC~50~ values of MR219 RBE were in the range of 95.44 to 111.50 μg/mL over the three different incubation periods ([Table 2](#tab1){ref-type="table"}).*" should be corrected to "*Based on the results, the IC~50~ values of MR219 RBE were in the range of 95.56 to 111.40 μg/mL over the three different incubation periods ([Table 2](#tab1){ref-type="table"}).*"

In addition, in the "Results" (Section 3.3), the text reading "*The positive effects were more distinctive with lower concentrations of RBE (BJLN: 25 μg/mL; MR219: 50 μg/mL) with observable increments in IC~50~ of H~2~O~2~ (BJLN: 645.65 μM; MR219: 320.63 μM) ([Table 4](#tab2){ref-type="table"}) when compared to negative control (316.23 μM). When the two extracts were compared, BJLN (25 μg/mL) extract outran MR219 (50 μg/mL) extract in terms of efficacy with a significant increment in IC~50~ of H~2~O~2~ approximately twofold (645.65 μM)* versus *1.4% (in approximation) when compared to negative control (316.23 μM).*" should be replaced with "*The positive effects were more distinctive with lower concentrations of RBE (BJLN: 25 μg/mL; MR219: 50 μg/mL) with observable increments in IC~50~ of H~2~O~2~ (BJLN: 597.20 μM; MR219: 364.20 μM) ([Table 4](#tab2){ref-type="table"}) when compared to negative control (271.00 μM). When the two extracts were compared, BJLN (25 μg/mL) extract outran MR219 (50 μg/mL) extract in terms of efficacy with a significant increment in IC~50~ of H~2~O~2~ by approximately 2-fold (597.20 μM)* versus *1.4-fold (in approximation) when compared to negative control (271.00 μM).*", and the text reading "*Significant decrements in the IC~50~ values of H~2~O~2~ were found for cell pretreated with 50 μg/mL BJLN (92.90 μM) and 100 μg/mL MR219 (171.79 μM) extracts when compared to negative control (316.23 μM) ([Table 4](#tab2){ref-type="table"}). The higher concentrations of BJLN and MR219 extracts selected were near the range of IC~50~ of both extracts (IC~50~ of BJLN: 52.18 μg/mL to 73.09 μg/mL; IC~50~ of MR219: 95.44 μg/mL to 111.50 μg/mL).*" should be replaced with "*Significant decrements in the IC~50~ values of H~2~O~2~ were found for cell pretreated with 50 μg/mL BJLN (89.95 μM) and 100 μg/mL MR219 (143.90 μM) extracts when compared to negative control (271.00 μM) ([Table 4](#tab2){ref-type="table"}). The higher concentrations of BJLN and MR219 extracts selected were near the range of IC~50~ of both extracts (IC~50~ of BJLN: 59.57 μg/mL to 64.27 μg/mL; IC~50~ of MR219: 95.56 μg/mL to 111.40 μg/mL)*."

An incorrect version of [Figure 3](#fig3){ref-type="fig"} with missing graphical elements was published. The corrected version of [Figure 3](#fig3){ref-type="fig"} with the inclusion of graphical elements is as shown below.

Accordingly, [Figure 5(b)](#fig5){ref-type="fig"} presented in the original manuscript was also the incorrect version. The fourth datum point for MR219 (50 *μ*g/mL) (grey dotted line) was incorrectly plotted. The correct version of the figure is as shown below with the corrected fourth datum point for MR219 (50 *μ*g/mL) (grey dotted line).

![Total contents of selected bioactive compounds in the RBE. Different letters on a bar represent significant differences at *P* ≤ 0.05 (Tukey\'s test).](OMCL2018-3136860.003){#fig3}

![Effects of H~2~O~2~ inductions on cell viabilities of H9c2(2-1) cardiomyocytes pretreated with different concentrations of (a) BJLN RBE (25 *μ*g/mL and 50 *μ*g/mL) and (b) MR219 RBE (50 *μ*g/mL and 100 *μ*g/mL).](OMCL2018-3136860.005){#fig5}

###### 

The relative inhibitory concentration (IC~50~) of RBE of BJLN and MR219. Data presented as mean ± standard deviation of three technical replicates (*n* = 3).

  -------------------------------------------------------------
               BJLN            MR219                   
  ------------ --------------- ------- --------------- --------
  Day 1\       1.808 ± 0.011   64.27   1.980 ± 0.013   95.56
  (24 hours)                                           

  Day 2\       1.775 ± 0.002   59.57   2.047 ± 0.026   111.40
  (48 hours)                                           

  Day 3\       1.800 ± 0.004   63.10   2.033 ± 0.029   108.00
  (72 hours)                                           
  -------------------------------------------------------------

###### 

Average IC~50~ of H~2~O~2~ for H9c2(2-1) cells. The IC~50~ value was determined from respective cell viability curves ( [Figure 5](#fig5){ref-type="fig"}) via GraphPad Prism (GraphPad Software Inc., USA). Data represent mean ± standard deviation of 3 (*n* = 3). ∗ denotes significantly different from negative control treated with media + 1% EtOH at *P* ≤ 0.05. Graphical representations of data were depicted in [Figure 5](#fig5){ref-type="fig"}.

                                        Average IC~50~ of H~2~O~2~ (*μ*M)   
  ------------------------------------- ----------------------------------- --------
  Control sample                                                            
   Negative control (media + 1% EtOH)   2.433 ± 0.040                       271.00
  RBE                                                                       
   BJLN (25 *μ*g/mL)                    2.776 ± 0.028^∗^                    597.20
   BJLN (50 *μ*g/mL)                    1.954 ± 0.033^∗^                    89.95
   MR219 (50 *μ*g/mL)                   2.561 ± 0.035^∗^                    364.20
   MR219 (100 *μ*g/mL)                  2.158 ± 0.032^∗^                    143.90
